All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Organization Postal Address | NCIT_C93875 | [A contact point used to send physical forms of communication to the organization.] |
| Dreaming | NCIT_C54268 | [A mental phenomenon occurring during sleep in which images, emotions, and thoughts are experienced with a sense of reality; occurs during REM sleep.] |
| Conation | NCIT_C26440 | [The conscious tendency to act, usually an aspect of mental process.] |
| Organization Relationship Effective Date Range | NCIT_C93876 | [The date and time span for when the organization relationship is active.] |
| Submitter | NCIT_C54269 | [A person who presents or submits something (e.g., a proposal or protocol) for formal consideration or review by others.] |
| Organization Relationship Type Code | NCIT_C93877 | [A coded value specifying the kind of organization relationship.] |
| Ovarian Clear Cell Cystadenocarcinoma | NCIT_C7980 | [A malignant glandular epithelial neoplasm arising from the ovary. It is characterized by the presence of clear and hobnail cells and cystic structures.] |
| Organization Type Code | NCIT_C93878 | [A coded value specifying the kind of organization.] |
| Organizational Contact Effective Date Range | NCIT_C93879 | [The date and time span for when the organizational contact is active.] |
| Thymoma Type B3 | NCIT_C7997 | [Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma. The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors. It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.] |
| Thymic Lymphoepithelioma-Like Carcinoma | NCIT_C7998 | [A rare, usually aggressive primary thymic carcinoma, characterized by a syncytial growth of undifferentiated carcinoma cells and the presence of a lymphoplasmacytic infiltrate. More than 40% of cases are associated with Epstein-Barr virus infection.] |
| Malignant Type A Thymoma | NCIT_C7999 | [A type A thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.] |
| Parathyroid Gland Clear Cell Adenoma | NCIT_C7993 | [A parathyroid gland adenoma composed predominantly of neoplastic cells with clear cytoplasm.] |
| Benign Parathyroid Gland Adenoma | NCIT_C156757 | [A parathyroid gland adenoma that lacks the morphologic characteristics of parathyroid gland carcinoma and there is no evidence of capsular invasion, vascular invasion, and perineural invasion.] |
| Parathyroid Gland Mixed Cell Type Adenoma | NCIT_C7994 | [A parathyroid gland adenoma that contains a mixture of neoplastic cells (chief cells, oncocytes, and clear cells).] |
| Mixed Cell Adenoma | NCIT_C4157 | [An adenoma characterized by the presence of a mixed epithelial cell population.] |
| Granular Renal Cell Carcinoma | NCIT_C7995 | [A renal cell carcinoma with eosinophilic cytoplasm and high nuclear grade. Granular cells can be seen in any subtype of renal cell carcinoma, including conventional clear cell carcinoma. This term does not represent a specific subtype of renal cell carcinoma and should no longer be used.] |
| Malignant Type B1 Thymoma | NCIT_C7996 | [A type B1 thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.] |
| Thymoma Type B1 | NCIT_C6887 | [A thymic epithelial neoplasm characterized by the presence of expanded areas which resemble the normal thymic cortex. The neoplastic epithelial cells are small and scant and there is a dense T-lymphocytic component present. Areas of medullary differentiation with or without Hassall's corpuscles are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It has a low grade malignant potential. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II tumors.] |
| Material Effective Date Range | NCIT_C93860 | [The date and time span for when the material is active.] |